KR970032857A - Pharmaceutical composition - Google Patents

Abstract

The present invention relates to a pharmaceutical composition, and more particularly, to simultaneously contain a zincolide derivative having an effect as a platelet activating factor (PAF) receptor antagonist and a thiazolidine derivative having activity as a 5-lipooxygenase inhibitor. The present invention relates to a novel pharmaceutical composition useful for the prevention and treatment of inflammatory or allergic diseases caused by such substances by effectively inhibiting the production of platelet activators and leukotrienes in vivo by synergistic action between two compounds.

Description

Pharmaceutical composition

Since this is an open matter, no full text was included.

Claims (2)

A pharmaceutical composition containing a zinc chloride derivative represented by the following structural formula (I) and a thiazolidine derivative represented by the following structural formula (II). Wherein R ² represents a hydrogen atom or R ¹ , and R ¹ represents -A-Ar, -AZ-Ar, -CO-Ar, SO ₂ -Ar, -A-Het, or -A-NR ⁴ R ⁵ represents a, where a is C ₁ ~ C ₈ alkyl group, or C ₁ ~ C ₅ straight or represents alkylene of C ₁ ~ C ₈ alkyl group substituted with a group of the side chain; Z represents a carbon, oxygen, sulfur or nitrogen atom; Ar is a substituted phenyl group having 1 to 5 phenyl groups, pyridyl groups, naphthyri, pyrimidyl groups, quinolyl groups, or functional groups. A pyridyl group, a naphthyl group, a pyrimidyl group or a quinolyl group; Het, represents a saturated or unsaturated heterocyclic group containing one or more nitrogen, oxygen or sulfur atoms; R 4 and R 5 are the same as or different from each other, and represent a hydrogen atom, an alkyl group, or a cycloalkyl group. In this case, a functional group which may be substituted with Ar is a hydrogen atom, a halogen atom, a hydroxyl group, a carboxylic acid group, a C ₁ -C ₁₀ alkyl group, a C ₁ ~ C ₁₀ alkenyl group, C ₁ ~ C ₁₀ alkynyl group, C ₁ -C ₁₀ haloalkyl group, C ₁ -C ₁₀ alkoxy group, C ₁ -C ₁₀ alkenyloxy group, C ₁ -C ₁₀ alkynyloxy group, C ₁ -C ₁₀ haloalkoxy group, phenyl group, Phenoxy group, aralkyl group, aralkyloxy group, substituted phenyl group, substituted phenoxy group, substituted aralkyl group, substituted aralkyloxy group, COR ⁴ , -CONR ⁴ R ⁵ , -CO ₂ R ⁴ , -NHCOR ⁴ ,- NH (OH), -N (OH) COR ⁴ , -CH ₂ OR ⁴ , -OCH ₂ CO ₂ R ⁴ , -CH ₂ SR ⁴ , -CH ₂ NR ⁴ R ⁵ , -SR ⁴ , -OSR ⁴ ,- SO ₂ NR ⁴ R ⁵ , -NR ⁴ R ⁵ , NR ⁴ SO ₂ R ⁵ , wherein r ⁴ and R ⁵ are the same as or different from each other and are each selected from a hydrogen atom, a C ₁ to C ₁₀ alkyl group or a C ₃ to C ₁₀ A cycloalkyl group.)-SCX ₃ (X is a halogen atom), -CN, -NO ₂ or -ZA-Z '-(Z is A as defined above and Z' is each Carbon, oxygen sulfur or nitrogen atom), N is 0,1,2 or 3, Q represents an alkyl group, a phenyl group, a substituted phenyl group or a pyridyl group, and G ¹ , G ² and G ³ are each the same or Others represent a hydrogen atom, an alkyl group, a cycloalkyl group, a phenyl group, a substituted phenyl group, and G ⁴ , G ⁵ , G ⁶ , G ⁷ and G ⁸ each represent the same or different hydrogen atoms, hydroxyl groups, halogen atoms, alkyl groups. , Alkoxy group, nitro group, amino group, substituted amino group, haloalkyl group, ralkoxyoxy group (Wherein G ¹⁵ represents an alkyl group), T is a hydrogen atom, a hydroxyl group, an alkyl group,-(CH ₃ ) ₂ -OG ¹⁰ , Or-(CH ₂ ) ₃ -NG ¹³ G ¹⁴ . Wherein m is 1,2,3 or 4; G ⁹ is a hydrogen atom, a phenyl group, a substituted phenyl group or a pyridyl group; G ¹⁰ is a hydrogen atom, an alkyl group or an alkanoyl group; G ¹¹ is an alkyl group, an alkoxy group or a substituted amino group; G ¹² is an alkyl group or a phenyl group; G ¹⁶ is a hydrogen atom or an alkyl group; G ^{13 is a} hydrogen atom, an alkyl group or an alkanoyl group; G ¹⁴ represents a hydrogen atom, an alkyl group or a cycloamino group alternatively containing a 5- to 7-membered cycloamino group, a substituted cycloamino group or another hetero atom, to which G ¹³ and G ¹⁴ are connected to each other. The pharmaceutical composition according to claim 1, wherein the zincolide derivative represented by the structural formula (I) and the thiazolidine derivative represented by the structural formula (II) are mixed at a weight ratio of 1: 3 to 3: 1. ※ Note: The disclosure is based on the initial application.